Singletto Inc. — SEC Form D Filing
Singletto Inc. filed an SEC Form D on March 5, 2026, reporting $100K raised in Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- March 5, 2026
- Amount reported
- $100K
- Round stage
- Seed
- Industry
- Health Care
- Website
- https://www.singletto.com/
What the company does
Securities: Debt. Exemption: Rule 506(b). Incorporated: WASHINGTON
Problem
Existing antimicrobial technologies have been unable to support the demand for effective products in critical environments.
Solution
Singletto's Oxafence technology integrates antimicrobial performance directly into materials, enabling new product categories that meet unmet needs.
Why now
The need for effective antimicrobial solutions has intensified due to recent global health challenges.
Verdict
Investors said yes at this moment because Singletto's narrative tied directly to an accelerating demand for effective antimicrobial solutions amid global health concerns, not merely because of a novel technology. They were betting on the integration of antimicrobial performance into materials addressing critical market gaps, which implied a potential shift in product development across various healthcare settings. However, limited upside comes from the risk of commoditization of antimicrobial technologies, as passive strategies may quickly evolve to meet demand without significantly differentiating from competitors.
Source: SEC EDGAR Form D filing